Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 14;10(8):ofad354. doi: 10.1093/ofid/ofad354

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 2. — Patient enrollment and treatment assignment (sotrovimab). ^aITT population includes all randomly assigned participants, excluding those who were immunocompetent and fully vaccinated under the original protocol. ^bPrimary analysis population is defined as the ITT population minus those who violated key inclusion/exclusion criteria. ^cThe as-treated (safety) population includes all participants who received the study treatment. Two participants who were randomized to sotrovimab 500 mg IM received 250 mg IM and are included in the latter as-treated population. IM, intramuscular; IV, intravenous; ITT, intent to treat.